Provided by Tiger Trade Technology Pte. Ltd.

GRI BIO INC

1.88
-0.4400-18.97%
Post-market: 1.83-0.0500-2.66%19:45 EDT
Volume:642.77K
Turnover:1.36M
Market Cap:3.33M
PE:-0.02
High:2.16
Open:2.11
Low:1.81
Close:2.32
52wk High:80.36
52wk Low:1.81
Shares:1.77M
Float Shares:493.50K
Volume Ratio:3.92
T/O Rate:130.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-87.4667
EPS(LYR):-121.7987
ROE:-185.67%
ROA:-88.82%
PB:0.32
PE(LYR):-0.02

Loading ...

GRI Bio wins FDA orphan drug designation for GRI-0621 in pulmonary fibrosis

Reuters
·
Yesterday

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Yesterday

GRI Bio granted FDA orphan designation for tazarotene

TIPRANKS
·
Jun 17

Grupo Aeroportuario del Pacifico Publishes its 2025 Sustainability Report

GlobeNewswire
·
Jun 09

Aya Gold & Silver Releases its 2025 Sustainability Report

GlobeNewswire
·
Jun 04

Moody's Rates Danantara Investment at Baa2

Tempo
·
Jun 03

Colliers releases 2025 Global Sustainability Report

GlobeNewswire
·
Jun 02

Plexus Issues Fiscal 2025 Sustainability Report and Announces Transition to Absolute Emission Reduction Targets

GlobeNewswire
·
Jun 01

Kinross releases 2025 Sustainability Report

GlobeNewswire
·
Jun 01

GRI Bio Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Jun 01

Safe Bulkers, Inc. Announces Availability of 2025 Sustainability Report

GlobeNewswire
·
May 30

Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report

GlobeNewswire
·
May 20

From Growth to Symbiosis: The Evolution of Chinese Corporate Strategy

Deep News
·
May 20

Aura Announces its 2025 Sustainability Report

GlobeNewswire
·
May 20

GRI Bio CEO joins A.G.P. Healthcare Company Showcase fireside chat webcast

Reuters
·
May 18

GRI Bio Reports Q1 Financials with Positive Data for Idiopathic Pulmonary Fibrosis Drug

Deep News
·
May 15

GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate

Benzinga
·
May 14

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GlobeNewswire
·
May 14

GRI Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Gri Bio Q1 FY26 net loss narrows to $2 million from year-ago quarter

Reuters
·
May 14